Gilead Halts Magrolimab Blood Cancer Development After Increased Mortality Risk
February 7, 2024
Gilead Sciences is halting the development of magnolia for blood cancer, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), following an “increased risk of death” observed in a late-stage trial. This decision comes after the FDA placed a full clinical hold on the studies, stemming from findings that showed higher mortality rates due to infections and respiratory failure when magnolia was added to specific chemotherapy treatments. The ENHANCE-3 study in AML is being discontinued based on these safety concerns and the futility of the treatment. This marks a significant setback for Gilead, which acquired the drug through a $4.9 billion deal for Forty-Seven in 2020. Gilead will now refocus magnolia development on solid tumors while reviewing safety data. The company plans to update on its ongoing trials in solid tumors and share findings from the halted studies with regulatory authorities and the medical community.
To read more, click here.
[Source: Fierce Biotech, February 7th, 2024]
